ISB*

2):

In This Issue: March 2, 2021

Research

ORIGINAL INVESTIGATION

833 Effect of Postreinduction Therapy **Consolidation With Blinatumomab** vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

PA Brown and Coauthors

This randomized trial compares the effects of postreinduction therapy consolidation using blinatumomab, an antibody construct that links CD3+ T cells to CD19+ leukemia cells, vs chemotherapy on disease-free survival among children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia (ALL).

Fditorial 830 Related Article 843

■ Visual Abstract | CME

843 Effect of Blinatumomab vs Chemotherapy on Event-Free Survival **Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia:** A Randomized Clinical Trial

F Locatelli and Coauthors

This randomized trial compares the effects of blinatumomab, an antibody construct that links CD3+ T cells to CD19+ leukemia cells, vs consolidation chemotherapy as a third consolidation block before allogeneic hematopoietic stem cell transplant (HST) on event-free survival in children with high-risk first-relapse B-cell acute lymphoblastic leukemia (B-ALL)

Editorial 830 Related Article 833

Visual Abstract | CME

855 Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

N Ouldali and Coauthors for the French Covid-19 Paediatric Inflammation

This cohort study estimates the association of use of intravenous immunoglobulins (IVIG) plus methylprednisolone vs IVIG alone with treatment failure for multisystem inflammatory syndrome in children (MIS-C), defined as fever persistence at 2 days or fever recurrence within 7 days.

Opinion

VIEWPOINT

817 Regulation of Health Care Prices: The Case for Backstop Price Caps in Commercial Health Care Markets

ME Chernew and MJ Pany

819 Paying for Prescription Drugs in the New Administration

AS Kesselheim, TJ Hwang, and J Avorn

821 SARS-CoV-2 Vaccines and the Growing **Threat of Viral Variants**

JP Moore and PA Offit

Audio | Audio | Video

823 Data and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection

MA Honein, LC Barrios, and JT Brooks

825 Funding of Pharmaceutical Innovation **During and After the COVID-19 Pandemic** IC Robinson

A PIECE OF MY MIND

827 It's Not Your Fault

W Stead

In this narrative medicine essay an infectious diseases physician shares the sense of forgiveness she brings to anyone possibly involved in COVID-19 transmission, having learned as a child the healing power of family absolution after she witnessed the death of a cousin

EDITORIAL

829 Vaccine Distribution— **Equity Left Behind?**

M Jean-Jacques and H Bauchner

Audio | Audio | Video

830 Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia N Shukla and ML Sulis

Related Articles 833 and 843

Online at JAMA.com

ALIDIO

Editor's Summary of This Issue

Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

Live from AHA 2020: Highlights from the American Heart

Association's Virtual Scientific Sessions

Understanding SARS-CoV-2 Genetic Variants

Coronavirus Vaccine Update with Paul Offit and Robert Wachter

Coronavirus Vaccine Update With Paul Offit - February 11, 2021

Prioritizing Racial and Ethnic Minority Populations for Coronavirus Vaccination

Who Gets Coronavirus Vaccine First?

Irritable Bowel Syndrome-Diagnosis and Treatment

WIDEO

Coronavirus Vaccine Update With Paul Offit and Robert Wachter

Coronavirus Vaccine Update With Paul Offit - February 11, 2021

Prioritizing Racial and Ethnic Minority Populations for Coronavirus Vaccination

Who Gets Coronavirus Vaccine First?

E CME

Find CME quizzes online at jamacmelookup.com

INSTRUCTIONS FOR AUTHORS

jamanetwork.com/pages/for-authors

DEPARTMENTS

Staff Listing 805

Recruitment & Classified Advertising 807

CME Questions 882

Contact Information 897



Editor in Chief Howard Bauchner, MD

continued >

Available online



In This Issue: March 2, 2021

Clinical Review & Education

REVIEW

865 Diagnosis and Treatment of Irritable Bowel Syndrome: A Review

M Camilleri

This narrative review summarizes the epidemiology, pathophysiology, diagnosis, management, and prognosis of irritable bowel syndrome.

Audio | CME

JAMA INSIGHTS

878 Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021

P Mirmirani and J Fu

This JAMA Insights Clinical Update reviews the differential diagnosis, patterns, evaluation, and management of the most common causes of nonscarring hair loss, including male pattern balding, telogen effluvium, and alopecia areata.

FROM THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS

880 An EUA for Bamlanivimab— A Monoclonal Antibody for COVID-19

This Medical Letter review summarizes the evidence underlying the US Food and Drug Administration's emergency use authorization of bamlanivimab, an investigational neutralizing IgG1 monoclonal antibody for treatment of COVID-19, including specification of high-risk patient groups eligible for the drug and its dosage and administration.

JAMA PATIENT PAGE

898 Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines

EH Livingston

This JAMA Patient Page describes how the new Pfizer and Moderna COVID-19 vaccines available in the US work and explains why 2 doses of these vaccines are needed to confer adequate immunity.

Viewpoint 821

News & Analysis

MEDICAL NEWS & PERSPECTIVES

808 Researchers Investigate What COVID-19 Does to the Heart

LAbbasi

This Medical News article discusses reports of myocardial injury and myocarditis among patients with COVID-19.

Audio

812 Experts Discuss COVID-19— Vaccine Doses, Virus Variants, and More

JAMA Live Highlights features comments from livestream interviews by JAMA Network Editor in Chief Howard Bauchner, MD. His discussions with experts in clinical care, public health, and health policy focus on critical issues related to the *coronavirus disease 2019* (COVID-19) pandemic. Comments have been edited for clarity.

THE JAMA FORUM

814 Trade-offs in Public Health Insurance Design K Baicker

NEWS FROM THE FOOD AND DRUG ADMINISTRATION

816 Monthly Injection Is Approved for Patients With HIV

816 Rules Finalized for New Tobacco Product Approvals

816 Import Alert on Hand Sanitizers From South of the Border

Humanities

POETRY AND MEDICINE

892 Reason for Everything LE Claus

JAMA REVISITED

893 "A General Practitioner," or All for Mercy's Sake

Letters

RESEARCH LETTER

883 Change in Reported Adherence to Nonpharmaceutical Interventions During the COVID-19 Pandemic, April-November 2020

MA Crane and Coauthors

This study uses national survey data to describe overall and regional trends in adherence to protective behaviors (mask wearing, physical distancing, staying at home, others) among US adults during the COVID-19 pandemic from April to November 2020.

885 Association Between COVID-19
Lockdown Measures and Emergency
Department Visits for Violence-Related
Injuries in Cardiff, Wales

JP Shepherd and Coauthors

This study investigates emergency department visits for violence-related injuries occurring at home and outside the home in Cardiff, Wales, before and after COVID-19 lockdown measures were instituted in March 2020.

COMMENT & RESPONSE

The De-adoption of Low-Value Health Care 887 A Donzelli

In Reply

888 BW Powers, SH Jain, and WH Shrank

Antiretroviral Drug Recommendations for HIV Treatment and Prevention

888 N Shalev, KF Brudney, and ML Scherer

In Reply

889 MS Saag, RT Gandhi, and PE Sax

Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention

890 HK Kim, J Kubica, and Y-H Jeong

In Reply

890 SC You, A Gupta, and HM Krumholz